Member Info for dactions

Missthepenny62 - It's been a long-time coming with Falanx, they've taken so many business turns these past years, they really should be able to make a good fist of it now. The cyber market is so much more stronger than ever before, businesses have mostly realised the real need to protect their business against ransomware for example.

There is now a ready market out there from businesses willing to pay a reasonable monthly subscription to get protection. Falanx I feel were too lazy in the past expecting business to beat a path to its door. They had nonsensical packages on offer which they never followed-up. I tested this for myself for my own business but never had any Falanx follow-up whatsoever despite, as I thought, tempting them twice ! The SolarWinds link was largely hot air but now they have an opportunity where margins are fair and doable. If we see a continued uptake from the BoD in the next quarter, then I reckon they're now lean enough to turn a good profit and the shares will be worth investing in again. They know we're all concerned about their cash position which is why they are pushing this information to the market. It's taken them a long time to realise what they needed to do but I think they've learned it now.

In the meantime, I'll keep my holding as it is, having already lowered my average by adding at 1.25p a little while back.

Smart lady running MHC - she's nobodies fool that's for sure - and this is the first time I think we've actually heard that they've processed over 250,000 PCR tests up to date (safe to round up to start of October I'd say).

That is phenomenal for a new company - no wonder they've kept Boots sweet. Future looks good on what we heard today.

That spread is still wide.
Checked deals right now:
To Sell 1.6961
To Buy 1.876

SkippysB01 - fair point thanks and I did pick up on RM saying that - but the delay is still quite a fact to have to swallow.

HelloSanDiego - but why was Dr Mario at Kansas Hospital so bullish in his comments re Synairgen ?

It is disappointing to hear that likely end date has been pushed back several months. As a layman, I find it hard to understand why given the incredible numbers of serious cases of Covid around the world, it is taking so long to conclude the Sprinter trial.

However, as a long-time holder of Synairgen, I continue to believe in its efficacy and will continue to keep my shares.

Thank you Helen, but for you I would have missed it - I've now registered too.

From my experience, Penny's interview on Proactive was excellent - she made the valid point how their website is improving in the 'Google Space' - that is coming to the fore without having to buy google ads as I understand it. She was positive and aware how it will be important to promote 'wellness testing'.

Whatever the short-term reaction, I'm staying the course with my holding. May add on the dips - we'll see.

The figures are in line with what we were expecting - they are quite remarkable when you realise they've come from a base that none of us could have foreseen at the start.

The key number/fact in my mind is they are now cash generative - that is actual profit after all overheads. None of us have a crystal ball for the next 3 months but on balance the income should still be flowing given our contracts with Boots and Lloyds.

This is certainly not a share to trade - test of the market shortly after opening was: 2.39p Sell & 2.6p Buy

Sightwatcher - FILTERED

Lordpaul - I was really trying to explain why I thought the sp had not reacted as you had hoped - not having a go at you. I think I’ve been largely right but of course I’d like to see the sp higher just as anyone else.

Whether I stay the course with MHC, depends on what the BoD tell us Wednesday- I’d like to stick with them if possible. They have such a good chance to be a stunner of a share but have they management follow-through ?

GLA

Lord Paul - well, you did say in an earlier post that you'd like to 'Trade' the shares and on another post, you said you had £10,000 ready to top up - can't be both right ?!?

I think a lot of less experienced investors chased up this share originally and had their fingers burnt - so that has removed one route for growth. They have left the market probably. As far as I can see, there are no new Institutional Investors purchasing the shares - after all it was only 8 months ago that they bought in @1.75p. As far as I'm aware Oberon still maintain their 6% shareholding. So, without the froth of the smaller investors, the sp is going nowhere.

There are 22 millions shares in Company options but only 1 x 3rd vest not before next summer and then only at 3.5p - so that shouldn't cause wobbles in the stock market. The good news is, that barring some unthinkable bad news, like finding out our PCR tests were found useless and/or Boots cancel their agreement with MHC, the sp is not going to fall - it would be perverse thinking to believe otherwise. So right now could be a one-way ticket !

The figures are going to be excellent but at this Wednesday's publication of results, it will be knowledge of what the BoD announce as to what they will do with the money, that will really drive the share price.

Let's hope they're listening - GLA

"Agreed Liambooth, I think we have lost money who have bought at peak. There doesn’t seem any way they will make any profit at all."

Sightwatcher - where have you been all this time ?
1. FUM now has now have 3 major licensing deals under its belt from prominent Pharmas all negotiated during this dreadful pandemic.

2. It has received major funding to carry it forward from IIs and private investors at 40p placing.

3. The FDA has effectively implied approval from them will follow a 6 months effectiveness process which is already underway.

4. All deals involve continuous royalties on every sale.

5. Licensees meet all production costs.

6. EU & UK markets still being negotiated.

6. It's always difficult when one buys at the peak but subsequent falls don't justify negativity - they can be an opportunity to average down and there have been sufficient swings to achieve that.

7. Conversing with LiamBooth will turn you're head - best to FILTER them as their agenda is malicious in my opinion.

GLA

Well done FUM management - the potential is excellent joining up with Labatec Pharma - I know we don't have figures, they very wisely are keeping these under wraps as they bid for more markets collaboration worldwide. No doubt that product will be at Labatec's new manufacturing facility in Portugal.

It's time for a re-rate of the shareprice I reckon - the pieces are at last all falling together.

Of . . . oops . . . Oh for a different Chief Exec.
( a plea worth repeating in any case !).

I quite agree Bennoala - same here as for the years . When Woodward came on the scene I added - when they raised funds at equivalent now of £5 I added - when Woodward left I added - when they wanted yet more money at the 70p placing I didn't add as unfortunately no more money. All the time OH has done very well indeed financially - what exactly apart from his massive monthly pay check has really been added for those financing this business ?

Sour grapes ? - you bet.

The amount of information given to shareholders has been minuscule - I think I can now see why CFO Michael Hunt left after all those years. Of for a different Chief Exec.

Paul Nolan CEO did a really upbeat presentation last night in my opinion.

Although I've been a shareholder for many years, I learned so much more on their excellent forest sustainability policies - and particularly the ins & outs of the carbon credits market. I think I understood Paul Dolan to be looking for earnings in this market based on credits costing $10-20 a unit whereas I read only last night in a recent Telegraph article the current price is around $60 ! As we know, they have purchased massive acreage ready for new trees planting which will be financed by the big companies buying their carbon credits from Woodbois.

The other key fact heard last night was that they make 50% gross profit margin on their veneer sales. The 2nd line will be in place before year end and the 3rd veneer line (even greater in size than the other two) is scheduled for next year.

They're continuing to promise a quick turnaround of publication of the trading figures - he reckons 10 days. There are negatives such as every business is fighting for the shipping containers but he is still upbeat as to their trading and we can expect this to have been a good 3rd quarter which augers well for their other promise of a dividend next year based on 2021 results.

I don't usually give an opinion but I have this time - this share is so under the radar. GLA

I'd be really surprised if the sp reached 5p by Wednesday - confidence has taken a knock in the less experienced shareholders and I suspect they won't come back. We know the figures are going to be good - with Boots and Lloyds partnered - the company has to have performed well. You might say that the sp doesn't properly reflect the Boots connection in particular - that was a remarkable achievement by the Management to get them onside which has been largely ignored by the market in my opinion.

I think if it were to achieve 5p then the announcement and shareholder presentation on Wednesday needs to be substantive. Good numbers and believable projections are what's needed. Also, we need to know how they are going to maintain the revenues in the face of reduced Covid testing. It maybe the income that has been generated thus far could be used to buy out other current testers for example.

If we spot an 'outside the box' moment in their presentation, then I could foresee the sp moving into a higher range once again. Whether it'll be an easy tradeable stock that LORDPaul wants is very difficult to judge. The market makers have consistently widened the spread on very small volumes it seems to me.

GLA

Matterhorn - I can see your reasoning why you're sceptical but then you could ask, based on your sceptism, why would Synairgen need to be there if they already have enough contacts etc.

You have to agree though, Oxford12's find makes a nice read.

Woodbois Limited (AIM: WBI), the African focused forestry, timber trading, reforestation and voluntary carbon credit company is pleased to announce that the Company's Chair and CEO, Paul Dolan, will be presenting at Proactive Investors' One2One Virtual Forum today, Thursday 23 September 2021.

The event will commence at 6.00pm and will take place via online webinar.
If you would like to join the event, please register in advance at the following link: https://event.webinarjam.com/register/1233/8vvlqby1l

London Market - the answer is clear as it's on the US Embassy website as at 1st September whereby it is simply stated as a viral test - the full definition below - from which I assume is a PCR test.

What types of SARS-CoV-2 test are acceptable under the Order?
Passengers must be tested with a viral test that could be either an antigen test or a nucleic acid amplification test (NAAT). Examples of available NAATs for SARS-CoV-2 include but are not restricted to reverse transcription polymerase chain reaction (RT-PCR), reverse transcription loop-mediated isothermal amplification (RT-LAMP), transcription-mediated amplification (TMA), nicking enzyme amplification reaction (NEAR), and helicase-dependent amplification (HDA). The test used must be authorized for use by the relevant national authority for the detection of SARS-CoV-2 in the country where the test is administered. A viral test conducted for U.S. Department of Defense (DOD) personnel, including DOD contractors, dependents, and other U.S. government employees, and tested by a DOD laboratory located in a foreign country also meets the requirements of the Order.